One‐year results of the INSPIRE trial with the novel MGuard stent: Serial analysis with QCA and IVUS

Abstract

In this series of patients treated with MGuard stent, the novel device showed no midterm efficacy and safety concerns.

MGuard Mesh‐Covered Stent for Treatment of ST‐Segment Elevation Myocardial Infarction with High Thrombus Burden Despite Manual Aspiration

“…Actually, the membrane also prevented the endothelial ingrowth within the stent, which was eventually related to high rates of stent thrombosis as well as high rates of restenosis at the edges of the stent . In the case of the MGuard, however, it appears that the mesh does not prevent the neointimal proliferation within the stent . The rate of stent restenosis was low in our cohort.…”

“…17,18 In the case of the MGuard, however, it appears that the mesh does not prevent the neointimal proliferation within the stent. 19 The rate of stent restenosis was low in our cohort. Importantly, routine angiographic follow-up was not performed and therefore we cannot rule out the occurrence of restenosis that does not provoke ischemia or symptoms in an infarcted myocardial territory.…”

Endogenous adenosine maintains cartilage homeostasis and exogenous adenosine inhibits osteoarthritis progression

“…Extracellular adenosine derives mainly from hydrolysis of ATP (primarily, but not exclusively, by the ectoenzymes CD39 and CD73) and mediates its effects via activation of G-protein-coupled receptors (A1R, A2AR, A2BR and A3R). Adenosine has long been known to regulate inflammation and immune responses78 and work from our lab and others have demonstrated the importance of adenosine and its receptors in osteoblast, osteoclast, and bone marrow homeostasis9101112131415161718192021. Prior studies have suggested that adenosine receptors also regulate chondrocyte physiology and pathology in response to inflammatory stimuli in rodent, equine, bovine and human chondrocytes2223242526 although the specific receptor(s) involved are not identified.…”

Impact of a micro‐net mesh technology covering stent on coronary microvascular dysfunction in patients with high thrombus burden

“…Therefore, it appears that Mguard stent does not prevent neointimal proliferation. 37 Thus, further improvement in MNM technology covering stents should include a drug eluting technology for the prevention of restenosis as used by other coronary endo-protheses. The MNM interacts with the vessel wall and could therefore be used as a platform for drug coating in association with abluminal bioabsorbable polymer coating.…”